[
  {
    "ts": "2025-07-25T03:47:49+00:00",
    "headline": "Incyte Corp (INCY) Price Target Hiked at UBS on Sales and Earnings Growth Prospects",
    "summary": "Incyte Corporation (NASDAQ:INCY) is one of the best biotech stocks to buy according to billionaire Steve Cohen. On July 15, UBS reiterated a ‘Neutral’ rating on the stock and increased its price target to $62 from $61. The price hike comes as UBS expects higher sales for Incyte’s Niktimvo, a treatment for chronic Graft-versus-Host Disease […]",
    "url": "https://finance.yahoo.com/news/incyte-corp-incy-price-target-034749923.html",
    "source": "Insider Monkey",
    "provider": "yfinance",
    "raw": {
      "id": "576c86b6-7fba-3c43-b294-a634547d513b",
      "content": {
        "id": "576c86b6-7fba-3c43-b294-a634547d513b",
        "contentType": "STORY",
        "title": "Incyte Corp (INCY) Price Target Hiked at UBS on Sales and Earnings Growth Prospects",
        "description": "",
        "summary": "Incyte Corporation (NASDAQ:INCY) is one of the best biotech stocks to buy according to billionaire Steve Cohen. On July 15, UBS reiterated a ‘Neutral’ rating on the stock and increased its price target to $62 from $61. The price hike comes as UBS expects higher sales for Incyte’s Niktimvo, a treatment for chronic Graft-versus-Host Disease […]",
        "pubDate": "2025-07-25T03:47:49Z",
        "displayTime": "2025-07-25T03:47:49Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/insidermonkey.com/84b68424e224b15cde41dcaeb8a6611a",
          "originalWidth": 1456,
          "originalHeight": 816,
          "caption": "Incyte Corp (INCY) Price Target Hiked at UBS on Sales and Earnings Growth Prospects",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/21qc2zd2Eoz77N1CW776Ow--~B/aD04MTY7dz0xNDU2O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/insidermonkey.com/84b68424e224b15cde41dcaeb8a6611a.cf.webp",
              "width": 1456,
              "height": 816,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/sEnQRr2N.KPHUNql_NtN1Q--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/insidermonkey.com/84b68424e224b15cde41dcaeb8a6611a.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Insider Monkey",
          "url": "http://www.insidermonkey.com"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/incyte-corp-incy-price-target-034749923.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/incyte-corp-incy-price-target-034749923.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "INCY"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  }
]